ThinkSabio’s D9 TS Picks highlights three stocks with notable growth drivers, institutional interest and upcoming catalysts. 🔹 #IREN — IREN Limited IREN is expanding its AI Cloud business through major customer contracts and data-center capacity growth. FY2026 revenue increased 41% YoY to $707M, while AI Cloud revenue climbed nearly 8× to $128.8M. The company also reported $4B in contracted ARR for 2026 capacity. Resistance: $31.70, $33.01 Support: $27.84 👉 Detailed Analysis: https://t.me/c/2454754655/4545 🔹 #APPN — Appian Corporation Appian is benefiting from enterprise demand for low-code software and AI-powered process automation. Q1 FY2026 revenue reached $202.2M, up 21.5% YoY, while cloud subscription revenue grew 25%, supporting its enterprise digital-transformation opportunity. Resistance: $44.05, $46.00 Support: $40.50 👉 Detailed Analysis: https://t.me/c/2454754655/9368 🔹 #ZURA — Zura Bio Zura Bio is approaching key clinical catalysts for its investigational antibody tibulizumab, targeting autoimmune and inflammatory diseases. Phase 2 enrollment is complete in both HS (247 participants) and systemic sclerosis (91 participants), with HS topline data expected in Q4 2026. The company reported $205.1M in cash as of June 30, 2026. Resistance: $4.50, $4.80 Support: $3.85 👉 Detailed Analysis: https://t.me/c/2454754655/10438 🎯 Bottom Line IREN, APPN and ZURA each offer a different growth setup — AI data-center expansion, enterprise AI/automation adoption and clinical-stage biotech catalysts. Investors should evaluate valuation, execution, competitive risks and upcoming catalysts before making decisions. 🚀 Join ThinkSabio for Daily Stock Picks, Market News & Detailed Stock Analysis 🌐 ThinkSabio Community: https://www.thinksabio.com/community